Kennedy's disease clinical significance of tandem repeats in the androgen receptor

Advances in Experimental Medicine and Biology

Volumn 769, Issue , 2012, Pages 153-168

  Zajac, Jeffrey D ^a,b   Fui, Mark Ng Tang ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXY 1,7 BIS(3,4 DIMETHOXYPHENYL) 1,4,6 HEPTATRIEN 3 ONE; ADENINE; ALVESPIMYCIN; ANDROGEN RECEPTOR; ANTIANDROGEN; ASC J 9; C TERMINUS OF HEAT SHOCK COGNATE PROTEIN 70 INTERACTING PROTEIN; CREATINE KINASE; CYTOSINE; GUANINE; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; LEUPRORELIN; PLACEBO; SOMATOMEDIN C; TESTOSTERONE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ACUTE HEART FAILURE; ANDROGEN RECEPTOR GENE; ARM MUSCLE; ARTICLE; BULBAR PARALYSIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CYTOTOXICITY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MODEL; DRUG MECHANISM; DYSLIPIDEMIA; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; EXON; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FRACTURE; GAIT DISORDER; GENE EXPRESSION; GYNECOMASTIA; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPERGLYCEMIA; INFERTILITY; INSULIN RESISTANCE; KENNEDY DISEASE; LEG MUSCLE; METABOLIC DISORDER; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NEUROPHYSIOLOGY; NONHUMAN; OCCUPATIONAL THERAPY; OSTEOPOROSIS; PATHOGENESIS; PHENOTYPE; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN FUNCTION; REFLEX DISORDER; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; TANDEM REPEAT; UNSPECIFIED SIDE EFFECT; AR GENE; DYSARTHRIA; DYSPHAGIA; GAIN OF FUNCTION MUTATION; GENE; HAND TREMOR; LIMB WEAKNESS; LOSS OF FUNCTION MUTATION; PNEUMONIA;

ANIMALIA;

EID: 84934441995     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5434-2_10     Document Type: Article

References (83)

1. MacLean HE, Warne GL, Zajac JD. Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion. J Neurol Sci 1996; 135(2):149-157.
2. Lund A, Udd B, Juvonen V et al. Multiple founder effects in spinal and bulbar muscular atrophy (SBMA, Kennedy disease) around the world. Eur J Hum Genet 2001; 9(6):431-436.
3. Chahin N, Klein C, Mandrekar J et al. Natural history of spinal-bulbar muscular atrophy. Neurology 2008; 70(21):1967-1971.
4. MacLean HE, Choi WT, Rekaris G et al. Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy). J Clin Endocrinol Metab 1995; 80(2):508-516.
5. Atsuta N, Watanabe H, Ito M et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006; 129(Pt 6):1446-1455.
6. Hanajima R, Terao Y, Nakatani-Enomoto S et al. Postural tremor in X-linked spinal and bulbar muscular atrophy. Mov Disord 2009; 24(14):2063-2069.
7. Sperfeld AD, Hanemann CO, Ludolph AC et al. Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology 2005; 64(4):753-754.
8. Dejager S, Bry-Gauillard H, Bruckert E et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002; 87(8):3893-3901.
9. Zajac JD, MacLean HE. Kennedy's disease: clinical aspects. In: Wells RD, Warren ST, Sarmiento M, eds. Genetic Instabilities and Hereditary Neurological Diseases. San Diego: Academic Press; 1998:87-100.
10. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968; 18(7):671-680.
11. Lee JH, Shin JH, Park KP et al. Phenotypic variability in Kennedy's disease: implication of the early diagnostic features. Acta Neurol Scand 2005; 112(1):57-63.
12. Kassubek J, Juengling FD, Sperfeld AD. Widespread white matter changes in Kennedy disease: a voxel based morphometry study. J Neurol Neurosurg Psychiatry 2007; 78(11):1209-1212.
13. Soragna D, Messa C, Mochi M et al. Dopaminergic pathways involvement in Kennedy's disease: neurophysiological and. Journal of Neurology 2001; 248(8):710-712.
14. Shaw PJ, Thagesen H, Tomkins J et al. Kennedy's disease: unusual molecular pathologic and clinical features. Neurology 1998; 51(1):252-255.
15. Ishihara H, Kanda F, Nishio H et al. Clinical features and skewed X-chromosome inactivation in female carriers of X-linked recessive spinal and bulbar muscular atrophy. J Neurol 2001; 248(10):856-860.
16. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ et al. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002; 59(5):770-772.
17. Johansen JA, Yu Z, Mo K et al. Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy. Neurobiol Dis 2009; 34(1):113-120.
18. Ferrante MA, Wilbourn AJ. The characteristic electrodiagnostic features of Kennedy's disease. Muscle Nerve 1997; 20(3):323-329.
19. Suzuki K, Katsuno M, Banno H et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008; 131(Pt 1):229-239.
20. Sobue G, Hashizume Y, Mukai E et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989; 112(Pt 1):209-232.
21. Harding AE, Thomas PK, Baraitser M et al. X-linked recessive bulbospinal neuronopathy: a report of ten cases. J Neurol Neurosurg Psychiatry 1982; 45(11):1012-1019.
22. Li M, Sobue G, Doyu M et al. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression. Muscle Nerve 1995; 18(3):301-308.
23. Soraru G, D'Ascenzo C, Polo A et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. Journal of the Neurological Sciences 2008; 264(1-2):100-105.
24. Soukup GR, Sperfeld AD, Uttner I et al. Frontotemporal cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients. Journal of Neurology 2009; 256(11):1869-1875.
25. Logroscino G, Traynor BJ, Hardiman O et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008; 79(1):6-11.
26. McDermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. BMJ 2008; 336(7645): 658-662.
27. Corcia P, Meininger V. Management of amyotrophic lateral sclerosis. Drugs 2008; 68(8):1037-1048.
28. van der Graaff MM, de Jong JM, Baas F et al. Upper motor neuron and extra-motor neuron involvement in amyotrophic lateral sclerosis: a clinical and brain imaging review. Neuromuscul Disord 2009; 19(1):53-58.
29. Pugdahl K, Fuglsang-Frederiksen A, de Carvalho M et al. Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. J Neurol Neurosurg Psychiatry 2007; 78(7):746-749.
30. Amoiridis G, Tsimoulis D, Ameridou I. Clinical, electrophysiologic and pathologic evidence for sensory abnormalities in ALS. Neurology 2008; 71(10):779.
31. Suzuki K, Katsuno M, Banno H et al. The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry 2010; 81(5):567-571.
32. La Spada AR, Wilson EM, Lubahn DB et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352(6330):77-79.
33. Greenland KJ, Zajac JD. Kennedy's disease: pathogenesis and clinical approaches. Intern Med J 2004; 34(5):279-286.
34. Adachi H, Katsuno M, Minamiyama M et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005; 128(Pt 3):659-670.
35. Li M, Miwa S, Kobayashi Y et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Annals of Neurology 1998; 44(2):249-254.
36. Grossmann M, Thomas MC, Panagiotopoulos S et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93(5):1834-1840.
37. MacLean HE, Ball EM, Rekaris G et al. Novel androgen receptor gene mutations in Australian patients with complete androgen insensitivity syndrome. Hum Mutat 2004; 23(3):287.
38. Yeh S, Tsai MY, Xu Q et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA 2002; 99(21):13498-13503.
39. Notini AJ, Davey RA, McManus JF et al. Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 2005; 35(3):547-555.
40. Mariotti C, Castellotti B, Pareyson D et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul Disord 2000; 10(6):391-397.
41. Thomas PS Jr., Fraley GS, Damian V et al. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum Mol Genet 2006; 15(14):2225-2238.
42. Cary GA, La Spada AR. Androgen receptor function in motor neuron survival and degeneration. Phys Med Rehabil Clin N Am 2008; 19(3):479-494, viii.
43. Poletti A, Negri-Cesi P, Martini L. Reflections on the diseases linked to mutations ofthe androgen receptor. Endocrine 2005; 28(3):243-262.
44. Walsh R, Storey E, Stefani D et al. The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review. Neurotox Res 2005; 7(1-2):43-57.
45. McCampbell A, Taylor JP, Taye AA et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000; 9(14):2197-2202.
46. Minamiyama M, Katsuno M, Adachi H et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004; 13(11):1183-1192.
47. Walcott JL, Merry DE. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem 2002; 277(52):50855-50859.
48. Chan HY, Warrick JM, Andriola I et al. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Human Molecular Genetics 2002; 11(23):2895-2904.
49. Morfini G, Pigino G, Szebenyi G et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci 2006; 9(7):907-916.
50. Katsuno M, Adachi H, Minamiyama M et al. Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. Journal of Neuroscience 2010; 30(16):5702-5712.
51. Ellerby LM, Hackam AS, Propp SS et al. Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 1999; 72(1):185-195.
52. Adachi H, Katsuno M, Minamiyama M et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes ofthe spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 2003; 23(6):2203-2211.
53. Paulson HL, Perez MK, Trottier Y et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997; 19(2):333-344.
54. Li M, Nakagomi Y, Kobayashi Y et al. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 1998; 153(3):695-701.
55. Beitel LK, Scanlon T, Gottlieb B et al. Progress in spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamine-expanded androgen receptor. Neurotox Res 2005; 7(3):219-230.
56. Chevalier-Larsen ES, O'Brien CJ, Wang H et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 2004; 24(20):4778-4786.
57. Katsuno M, Banno H, Suzuki K et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9(9):875-884.
58. Matsumoto A, Micevych PE, Arnold AP. Androgen regulates synaptic input to motoneurons of the adult rat spinal cord. J Neurosci 1988; 8(11):4168-4176.
59. Goldstein LA, Sengelaub DR. Timing and duration of dihydrotestosterone treatment affect the development of motoneuron number and morphology in a sexually dimorphic rat spinal nucleus. J Comp Neurol 1992; 326(1):147-157.
60. Watson NV, Freeman LM, Breedlove SM. Neuronal size in the spinal nucleus ofthe bulbocavernosus: direct modulation by androgen in rats with mosaic androgen insensitivity. J Neurosci 2001; 21(3):1062-1066.
61. Schroder HD, Reske-Nielsen E. Preservation of the nucleus X-pelvic floor motosystem in amyotrophic lateral sclerosis. Clin Neuropathol 1984; 3(5):210-216.
62. Katsuno M, Adachi H, Minamiyama M et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. Journal of Neuroscience 2006; 26(47):12106-12117.
63. Takeyama K, Ito S, Yamamoto A et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002; 35(5):855-864.
64. McManamny P, Chy HS, Finkelstein DI et al. A mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2002; 11(18):2103-2111.
65. Abel A, Walcott J, Woods J et al. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum Mol Genet 2001; 10(2):107-116.
66. Kinirons P, Rouleau GA. Administration of testosterone results in reversible deterioration in Kennedy's disease. J Neurol Neurosurg Psychiatry 2008; 79(1):106-107.
67. Goldenberg JN, Bradley WG. Testosterone therapy and the pathogenesis of Kennedy's disease (X-linked bulbospinal muscular atrophy). Journal of the Neurological Sciences 1996; 135(2):158-161.
68. Katsuno M, Adachi H, Kume A et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002; 35(5):843-854.
69. Katsuno M, Adachi H, Doyu M et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003; 9(6):768-773.
70. Yang Z, Chang YJ, Yu IC et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007; 13(3):348-353.
71. Tokui K, Adachi H, Waza M et al. 17-DMAG ameliorates polyglutamine- mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Human Molecular Genetics 2009; 18(5):898-910.
72. Adachi H, Waza M, Tokui K et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. Journal of Neuroscience 2007; 27(19):5115-5126.
73. Palazzolo I, Stack C, Kong L et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009; 63(3):316-328.
74. Banno H, Katsuno M, Suzuki K et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Annals of Neurology 2009; 65(2):140-150.
75. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008; 93(6):2042-2049.
76. Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008; 93(1):2-7.
77. Grossmann M. Bone and metabolic health in patients with nonmetastatic prostate cancer receiving androgen deprivation therapy - management guidelines. Med J Aust. In Press.
78. Waza M, Adachi H, Katsuno M et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005; 11(10):1088-1095.
79. Banerji U, O'Donnell A, Scurr M et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23(18):4152-4161.
80. Piccioni F, Roman BR, Fischbeck KH et al. A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum Mol Genet 2004; 13(4):437-446.
81. Caplen NJ, Taylor JP, Statham VS et al. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum Mol Genet 2002; 11(2):175-184.
82. Takeuchi Y, Katsuno M, Banno H et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 2008; 38(2):964-971.
83. Banno H, Adachi H, Katsuno M et al. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Annals of Neurology 2006; 59(3):520-526.